Skip to main content

Table 3 Adverse cardiac Events in Patients on TKIs with and without DM

From: The association of QTc prolongation with cardiovascular events in cancer patients taking tyrosine kinase inhibitors (TKIs)

Adverse Event

Myocardial Infarction, n (%)

Heart Failure, n (%)

Stroke, n (%)

Cardiac Mortality, n (%)

All-Cause Mortality, n (%)

Yes

No

P Value

Yes

No

P Value

Yes

N o

P Value

Yes

No

P Value

Yes

No

P Value

Non-TKI

(n = 265)

               

Non DM

(n = 213)

65 (30.52)

148 (69.48)

0.9717

56 (26.29)

157 (73.71)

0.7092

14 (6.57)

199 (93.43)

0.7608

3 (1.41)

210 (98.59)

0.3894

79 (37.09)

134 (62.91)

0.7399

DM

(n = 52)

16 (30.77)

36 (69.23)

0.9717

15 (28.85)

37 (71.15)

0.7092

4 (7.69)

48 (92.31)

0.7608

0 (0.0)

52 (100.0)

0.3894

18 (34.62)

34 (65.38)

0.7399

TKIs

(n = 186)

               

Non DM

(n = 148)

35 (23.65)

113 (76.35)

0.7320

32 (21.62)

116 (78.38)

0.4264

5 (3.38)

143 (96.62)

0.0863

8 (5.41)

140 (94.59)

0.9723

61 (41.22)

87 (58.78)

0.9209

DM

(n = 38)

10 (26.32)

28 (73.68)

0.7320

6 (15.79)

32 (84.21)

0.4264

4 (10.53)

34 (89.47)

0.0863

2 (5.26)

36 (94.74)

0.9723

16 (42.11)

22 (57.89)

0.9209